Anika Therapeutics (NASDAQ: ANIK) reported Q3 EPS of $0.00, $0.35 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $41.5 million versus the consensus estimate of $38.27 million.

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.